AbbVie Acquires Gilgamesh Pharmaceuticals' Psychedelic Candidate Bretisilocin

October 20, 2025
AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals’ investigational compound bretisilocin, a next-generation psychedelic currently in Phase 2 trials for major depressive disorder.

AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals' investigational compound bretisilocin, announced in a press release. The compound is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for moderate-to-severe major depressive disorder.

Bretisilocin is designed as a next-generation psychedelic compound intended to address challenges seen with traditional psychedelics. AbbVie stated that recent clinical data suggest the compound has potential as a treatment for patients with major depressive disorder.

With the acquisition finalized, AbbVie plans to accelerate bretisilocin’s development as part of its psychiatry pipeline expansion.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

10/20
Sigma Defense Acquires Aries Defense to Expand CJADC2 and Tactical ISR Capabilities
10/20
C2A Security Acquires Vigilant Ops to Expand AI-Powered Product Security
10/20
Pentera Acquires DevOcean to Expand AI-Powered Cyber Risk Remediation
10/20
True Global Ventures Backs Prezent AI’s $30M Round and Acquisition of Prezentium
10/20
ServiceNow Acquires Work4Flow’s Now Assist Readiness Evaluation Tool

More from: Life Sciences

10/20
C2A Security Acquires Vigilant Ops to Expand AI-Powered Product Security
10/20
Cedar Launches Cedar Cover to Help Hospitals Manage Medicaid and Uninsured Patients
10/20
ProclaimRx Launches AI Platform for Pharmaceutical Commercial Intelligence
10/20
ESMO Issues First Guidelines for Safe Use of AI Language Models in Oncology
10/20
HDAI Unveils Real-Time AI Chart Summaries at HLTH 2025

Subscribe to AI Funding Brief

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like